董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| 曹卫 | 男 | Founder, Chairman of the Board and Chief Executive Officer | 64 | 未披露 | 8224.32 | 2023-04-25 |
| 徐国彤 | 男 | Director | 65 | 未披露 | 未持股 | 2023-04-25 |
| Wendy Hayes | 女 | Director | 53 | 未披露 | 未持股 | 2023-04-25 |
| 李建平 | 男 | Director | 54 | 未披露 | 未持股 | 2023-04-25 |
| 王国玮 | 男 | Director | 61 | 未披露 | 未持股 | 2023-04-25 |
高管介绍
注：高管持股数取自最新公司公告
董事简历
中英对照 | 中文 | 英文- 曹卫
-
曹卫 自 2017 年 5 月起担任 Gracell Biotechnologies Inc. 董事长兼首席执行官。曹博士在生物技术行业拥有超过 30 年的研发经验。在创立 Gracell Biotechnologies Inc. 公司之前，曹博士与人共同创立了 Cellular Biomedicine Group, Inc.，Cellular Biomedicine Group, Inc.致力于开发用于治疗癌症和退行性疾病的专有细胞疗法，并在 CBMG 担任多个职位，如首席运营官2010 年 8 月至 2016 年 1 月担任董事、首席执行官、董事。曹博士在哈佛医学院病理学系和斯坦福大学医学中心移植中心的免疫药理学领域拥有丰富的研究经验。曹博士拥有中国上海复旦大学医学院医学学士学位和博士学位。弗吉尼亚州里士满弗吉尼亚医学院药理学博士。曹博士拥有 80 多项先进细胞疗法的已授权专利和申请。
Wei Cao,has served as Gracell Biotechnologies Inc. Chairman of the Board and Chief Executive Officer since May 2017. Dr. Cao has over 30 years of research and development experience in the biotechnology industry. Prior to founding Gracell Biotechnologies Inc. company, Dr. Cao co-founded Cellular Biomedicine Group, Inc., a company engaging in developing proprietary cell therapies for the treatment of cancer and degenerative diseases, and served several positions at CBMG, such as chief operating officer, chief executive officer and director, from August 2010 to January 2016. Dr. Cao has extensive research experience in the immune-pharmacology field at Harvard Medical School Department of Pathology and Stanford University Medical Center Transplantation Center. Dr. Cao holds a Bachelor's degree in Medicine from Fudan University Medical College, Shanghai China, and a Ph.D. in Pharmacology from Medical College of Virginia, Richmond Virginia. Dr. Cao holds over 80 issued patents and applications for advanced cell therapies. - 曹卫 自 2017 年 5 月起担任 Gracell Biotechnologies Inc. 董事长兼首席执行官。曹博士在生物技术行业拥有超过 30 年的研发经验。在创立 Gracell Biotechnologies Inc. 公司之前，曹博士与人共同创立了 Cellular Biomedicine Group, Inc.，Cellular Biomedicine Group, Inc.致力于开发用于治疗癌症和退行性疾病的专有细胞疗法，并在 CBMG 担任多个职位，如首席运营官2010 年 8 月至 2016 年 1 月担任董事、首席执行官、董事。曹博士在哈佛医学院病理学系和斯坦福大学医学中心移植中心的免疫药理学领域拥有丰富的研究经验。曹博士拥有中国上海复旦大学医学院医学学士学位和博士学位。弗吉尼亚州里士满弗吉尼亚医学院药理学博士。曹博士拥有 80 多项先进细胞疗法的已授权专利和申请。
- Wei Cao,has served as Gracell Biotechnologies Inc. Chairman of the Board and Chief Executive Officer since May 2017. Dr. Cao has over 30 years of research and development experience in the biotechnology industry. Prior to founding Gracell Biotechnologies Inc. company, Dr. Cao co-founded Cellular Biomedicine Group, Inc., a company engaging in developing proprietary cell therapies for the treatment of cancer and degenerative diseases, and served several positions at CBMG, such as chief operating officer, chief executive officer and director, from August 2010 to January 2016. Dr. Cao has extensive research experience in the immune-pharmacology field at Harvard Medical School Department of Pathology and Stanford University Medical Center Transplantation Center. Dr. Cao holds a Bachelor's degree in Medicine from Fudan University Medical College, Shanghai China, and a Ph.D. in Pharmacology from Medical College of Virginia, Richmond Virginia. Dr. Cao holds over 80 issued patents and applications for advanced cell therapies.
- 徐国彤
-
徐国彤，2014年11月起，担任独立董事。他从2008年起，担任同济大学医学院的眼科与再生医学教授；以及是 Stem Cell Bank of TUSM的主任，该银行是中国干细胞研究和临床应用重要基地或中心。2008-2010年，在同济大学医学院担任副院长。在Alcon Lab和NEI/NIH作为博士后学习之后，被任命到北得克萨斯大学健康科学中心大学（University of North Texas Health Science Center）解剖学和细胞生物学系担任研究副教授。他于2007年在ISSCR合作举办了第一次大规模的国际干细胞研讨会。此后，他和他的同事发起成立中国干细胞生物学学会，并担任第一位会长。他还是国家干细胞与再生医学战略联盟（State Stem Cell & Regenerative Medicine Strategic Alliance）成立的活跃成员，以及担任委员会成员。他还是Chinese Journal of Cell and Stem Cell的副编辑。此外，他是中国为数不多的参与两个China National Major Projects 973计划的科学家之一Xu 持有North Texas Health Science Center的药理学博士学位，Peking Union Medical College和Chinese Academy of Medical Sciences的医学硕士学位，以及1982年从Harbin 医科大学获得的学士学位。
Guotong Xu,has served as Gracell Biotechnologies Inc. director since February 2019. We have determined that Guotong Xu meets the criteria for independence set forth in Rule 10A-3 of the Exchange Act. Dr. Xu has over 30 years of academia and industry experience in both China and the United States. Dr. Xu has been a professor of Ophthalmology and Pharmacology at Tongji University School of Medicine, or TUSM, since 2008 and a director of The East China Stem Cell Bank located inside TUSM, a center for stem cell research and clinical application in China. From March 2008 to July 2016, Dr. Xu served as dean of Tongji University School of Medicine. Dr. Xu has been an independent director of Guangzheng Group Co., Ltd., a company listed on the Shenzhen Stock Exchange (Stock Code: 002524) and Zhejiang Shapuaisi Pharmaceutical Co., Ltd., a company listed on the Shanghai Stock Exchange (Stock Code: 603168), from June 2018 and August 2020, respectively. Prior to that, Dr. Xu served as an independent director of Cellular Biomedicine Group Inc. from November 2014 to November 2016. Dr. Xu holds a Bachelor's degree in Medicine from Harbin Medical University, an M.D. and a Master of Medical Sciences from Peking Union Medical College, Chinese Academy of Medical Sciences, and a Ph.D. in Pharmacology from University of North Texas Health Science Center, Fort Worth, Texas. - 徐国彤，2014年11月起，担任独立董事。他从2008年起，担任同济大学医学院的眼科与再生医学教授；以及是 Stem Cell Bank of TUSM的主任，该银行是中国干细胞研究和临床应用重要基地或中心。2008-2010年，在同济大学医学院担任副院长。在Alcon Lab和NEI/NIH作为博士后学习之后，被任命到北得克萨斯大学健康科学中心大学（University of North Texas Health Science Center）解剖学和细胞生物学系担任研究副教授。他于2007年在ISSCR合作举办了第一次大规模的国际干细胞研讨会。此后，他和他的同事发起成立中国干细胞生物学学会，并担任第一位会长。他还是国家干细胞与再生医学战略联盟（State Stem Cell & Regenerative Medicine Strategic Alliance）成立的活跃成员，以及担任委员会成员。他还是Chinese Journal of Cell and Stem Cell的副编辑。此外，他是中国为数不多的参与两个China National Major Projects 973计划的科学家之一Xu 持有North Texas Health Science Center的药理学博士学位，Peking Union Medical College和Chinese Academy of Medical Sciences的医学硕士学位，以及1982年从Harbin 医科大学获得的学士学位。
- Guotong Xu,has served as Gracell Biotechnologies Inc. director since February 2019. We have determined that Guotong Xu meets the criteria for independence set forth in Rule 10A-3 of the Exchange Act. Dr. Xu has over 30 years of academia and industry experience in both China and the United States. Dr. Xu has been a professor of Ophthalmology and Pharmacology at Tongji University School of Medicine, or TUSM, since 2008 and a director of The East China Stem Cell Bank located inside TUSM, a center for stem cell research and clinical application in China. From March 2008 to July 2016, Dr. Xu served as dean of Tongji University School of Medicine. Dr. Xu has been an independent director of Guangzheng Group Co., Ltd., a company listed on the Shenzhen Stock Exchange (Stock Code: 002524) and Zhejiang Shapuaisi Pharmaceutical Co., Ltd., a company listed on the Shanghai Stock Exchange (Stock Code: 603168), from June 2018 and August 2020, respectively. Prior to that, Dr. Xu served as an independent director of Cellular Biomedicine Group Inc. from November 2014 to November 2016. Dr. Xu holds a Bachelor's degree in Medicine from Harbin Medical University, an M.D. and a Master of Medical Sciences from Peking Union Medical College, Chinese Academy of Medical Sciences, and a Ph.D. in Pharmacology from University of North Texas Health Science Center, Fort Worth, Texas.
- Wendy Hayes
-
Wendy Hayes ，自2020年6月起担任Burning Rock Biotech Limited独立董事。她曾担任Tuanche Limited （NASDAQ： TC）的独立董事（2018年11月以来）、iHuman Inc. （NYSE： IH）、Gracell Biotechnologies Inc. （NASDAQ： GRCL）（2021年1月以来）、SciClone Pharmaceuticals （Holdings） Limited （HKEX： 6600）（2021年3月以来）。2013年5月至2018年9月，她曾担任the Public Company Accounting Oversight Board在美国的检查主管。在此之前，她曾担任Deloitte （中国）的审计合伙人。她于1991年获得对外经济贸易大学国际金融学士学位，并于2012年获得张Kong Graduate School of Business的emba学位。她目前是哈佛大学ALI的高级研究员。她是美国（加州）和中国的注册会计师。
Wendy Hayes,serves as a member of Apollomics Inc. board of directors. Ms. Hayes serves on the boards of directors of multiple public companies, including SharkNinja, Inc. (NYSE: SN) since July 2023, SciClone Pharmaceuticals (Holdings) Ltd (HK: 6600) since March 2021, iHuman Inc. (NYSE: IH) since October 2020, Burning Rock Biotech Limited (NASDAQ: BNR) since June 2020 and Tuanche Limited (NASDAQ: TC) since November 2018. Ms. Hayes previously served on the board of TuSimple (Nasdaq: TSP) from December 2022 to December 2023, and Gracell Biotechnologies Inc. (NASDAQ: GRCL) from January 2021 to February 2023. From May 2013 to September 2018, Ms. Hayes served as the Inspections Leader at the Public Company Accounting Oversight Board in the United States. Prior to that, Ms. Hayes was an audit partner at Deloitte (China). Ms. Hayes is a certified public accountant in the United States (California) and in China. Ms. Hayes received her bachelor's degree in international finance from the University of International Business and Economics in Beijing and received an MBA from Cheung Kong Graduate School of Business in Shanghai. - Wendy Hayes ，自2020年6月起担任Burning Rock Biotech Limited独立董事。她曾担任Tuanche Limited （NASDAQ： TC）的独立董事（2018年11月以来）、iHuman Inc. （NYSE： IH）、Gracell Biotechnologies Inc. （NASDAQ： GRCL）（2021年1月以来）、SciClone Pharmaceuticals （Holdings） Limited （HKEX： 6600）（2021年3月以来）。2013年5月至2018年9月，她曾担任the Public Company Accounting Oversight Board在美国的检查主管。在此之前，她曾担任Deloitte （中国）的审计合伙人。她于1991年获得对外经济贸易大学国际金融学士学位，并于2012年获得张Kong Graduate School of Business的emba学位。她目前是哈佛大学ALI的高级研究员。她是美国（加州）和中国的注册会计师。
- Wendy Hayes,serves as a member of Apollomics Inc. board of directors. Ms. Hayes serves on the boards of directors of multiple public companies, including SharkNinja, Inc. (NYSE: SN) since July 2023, SciClone Pharmaceuticals (Holdings) Ltd (HK: 6600) since March 2021, iHuman Inc. (NYSE: IH) since October 2020, Burning Rock Biotech Limited (NASDAQ: BNR) since June 2020 and Tuanche Limited (NASDAQ: TC) since November 2018. Ms. Hayes previously served on the board of TuSimple (Nasdaq: TSP) from December 2022 to December 2023, and Gracell Biotechnologies Inc. (NASDAQ: GRCL) from January 2021 to February 2023. From May 2013 to September 2018, Ms. Hayes served as the Inspections Leader at the Public Company Accounting Oversight Board in the United States. Prior to that, Ms. Hayes was an audit partner at Deloitte (China). Ms. Hayes is a certified public accountant in the United States (California) and in China. Ms. Hayes received her bachelor's degree in international finance from the University of International Business and Economics in Beijing and received an MBA from Cheung Kong Graduate School of Business in Shanghai.
- 李建平
-
李建平， 从2021年7月起担任董事。Lee先生拥有超过16年的资产管理经验。Lee 先生目前是莲花资产管理有限公司的首席执行官。2019年6月至2019年9月，Lee 先生是郑和资本管理有限公司的持牌代表，从事《证券及期货条例》或《证券及期货条例》规定的第4类和第9类受监管活动。2019年1月至2019年5月，Lee 先生担任莲花资产管理有限公司负责人，负责《证券及期货条例》规定的第4类和第9类受监管活动。2015年7月至2018年7月，Lee 先生是MZ资产管理有限公司的负责人，负责《证券及期货条例》下的第9类受监管活动。2014年5月至2014年8月，Lee 先生是Fenex Capital Management Limited的负责人，负责《证券及期货条例》下的第9类受监管活动。Lee 先生是2010年9月至2011年11月在SFO进行的9型管制活动的持牌代表，以及在前哨管理香港2010年11月至2011年3月的SFO下进行的第9类规范活动的负责人；2012年3月至2017年3月，Lee 先生担任Orbunneich Medical Company Ltd.的首席财务官，2017年3月至2018年6月担任其高级顾问。2000年8月至2010年8月，Lee 先生在新鸿基集团公司工作，最后一个职位是企业发展负责人。1997年2月至2000年7月，Lee 先生在高盛（亚洲）有限责任公司工作，最后一个职位是投资管理部执行董事。Lee 先生于2013年3月至2019年3月被香港特区政府委任为香港金融服务发展局新业务委员会的委员。Lee 先生是2004年9月至2012年8月的另类投资管理协会香港分会主席。Lee 先生于2007年6月至2009年5月被香港特区政府委任为证券及期货事务监察委员会顾问委员会成员。Lee 先生于1991获宾夕法尼亚大学应用科学学士学位。
Christophe Kin Ping Lee,has served as Gracell Biotechnologies Inc. director since July 2021. We have determined that Christophe Kin Ping Lee meets the criteria for independence set forth in Rule 10A-3 of the Exchange Act. Mr. Lee has over 16 years of experience in asset management. Mr. Lee is currently the chief executive officer of Lotus Asset Management Limited. From June 2019 to September 2019, Mr. Lee was a licensed representative of Zheng He Capital Management Limited for Type 4 and Type 9 regulated activities under the Securities and Futures Ordinance, or the SFO. From January 2019 to May 2019, Mr. Lee served as a responsible officer of Lotus Asset Management Limited for Type 4 and Type 9 regulated activities under the SFO. From July 2015 to July 2018, Mr. Lee was a responsible officer of MZ Asset Management Limited for Type 9 regulated activities under the SFO. From May 2014 to August 2014, Mr. Lee was a responsible officer of Fenex Capital Management Limited for Type 9 regulated activities under the SFO. Mr. Lee was a licensed representative for Type 9 regulated activities under the SFO from September 2010 to November 2011 and a responsible officer for Type 9 regulated activities under the SFO from November 2010 to March 2011 of FrontPoint Management (Hong Kong), Ltd. Mr. Lee was the chief financial officer of OrbusNeich Medical Company Ltd. from March 2012 to March 2017, and its senior advisor from March 2017 to June 2018. Mr. Lee worked in Sun Hung Kai & Co. group companies from August 2000 to August 2010 with his last position as Head of Corporate Development. Mr. Lee worked in Goldman Sachs (Asia) LLC from February 1997 to July 2000 with his last position as executive director of the Investment Management Division. Mr. Lee was appointed as a committee member of the New Business Committee of the Financial Services Development Council of Hong Kong by the Hong Kong SAR government from March 2013 to March 2019. Mr. Lee was the chairman of the Hong Kong Branch of the Alternative Investment Management Association from September 2004 to August 2012. Mr. Lee was appointed as a member of the Securities and Futures Commission Advisory Committee by the Hong Kong SAR government from June 2007 to May 2009. Mr. Lee received a Bachelor of Applied Science Degree from the University of Pennsylvania in 1991. - 李建平， 从2021年7月起担任董事。Lee先生拥有超过16年的资产管理经验。Lee 先生目前是莲花资产管理有限公司的首席执行官。2019年6月至2019年9月，Lee 先生是郑和资本管理有限公司的持牌代表，从事《证券及期货条例》或《证券及期货条例》规定的第4类和第9类受监管活动。2019年1月至2019年5月，Lee 先生担任莲花资产管理有限公司负责人，负责《证券及期货条例》规定的第4类和第9类受监管活动。2015年7月至2018年7月，Lee 先生是MZ资产管理有限公司的负责人，负责《证券及期货条例》下的第9类受监管活动。2014年5月至2014年8月，Lee 先生是Fenex Capital Management Limited的负责人，负责《证券及期货条例》下的第9类受监管活动。Lee 先生是2010年9月至2011年11月在SFO进行的9型管制活动的持牌代表，以及在前哨管理香港2010年11月至2011年3月的SFO下进行的第9类规范活动的负责人；2012年3月至2017年3月，Lee 先生担任Orbunneich Medical Company Ltd.的首席财务官，2017年3月至2018年6月担任其高级顾问。2000年8月至2010年8月，Lee 先生在新鸿基集团公司工作，最后一个职位是企业发展负责人。1997年2月至2000年7月，Lee 先生在高盛（亚洲）有限责任公司工作，最后一个职位是投资管理部执行董事。Lee 先生于2013年3月至2019年3月被香港特区政府委任为香港金融服务发展局新业务委员会的委员。Lee 先生是2004年9月至2012年8月的另类投资管理协会香港分会主席。Lee 先生于2007年6月至2009年5月被香港特区政府委任为证券及期货事务监察委员会顾问委员会成员。Lee 先生于1991获宾夕法尼亚大学应用科学学士学位。
- Christophe Kin Ping Lee,has served as Gracell Biotechnologies Inc. director since July 2021. We have determined that Christophe Kin Ping Lee meets the criteria for independence set forth in Rule 10A-3 of the Exchange Act. Mr. Lee has over 16 years of experience in asset management. Mr. Lee is currently the chief executive officer of Lotus Asset Management Limited. From June 2019 to September 2019, Mr. Lee was a licensed representative of Zheng He Capital Management Limited for Type 4 and Type 9 regulated activities under the Securities and Futures Ordinance, or the SFO. From January 2019 to May 2019, Mr. Lee served as a responsible officer of Lotus Asset Management Limited for Type 4 and Type 9 regulated activities under the SFO. From July 2015 to July 2018, Mr. Lee was a responsible officer of MZ Asset Management Limited for Type 9 regulated activities under the SFO. From May 2014 to August 2014, Mr. Lee was a responsible officer of Fenex Capital Management Limited for Type 9 regulated activities under the SFO. Mr. Lee was a licensed representative for Type 9 regulated activities under the SFO from September 2010 to November 2011 and a responsible officer for Type 9 regulated activities under the SFO from November 2010 to March 2011 of FrontPoint Management (Hong Kong), Ltd. Mr. Lee was the chief financial officer of OrbusNeich Medical Company Ltd. from March 2012 to March 2017, and its senior advisor from March 2017 to June 2018. Mr. Lee worked in Sun Hung Kai & Co. group companies from August 2000 to August 2010 with his last position as Head of Corporate Development. Mr. Lee worked in Goldman Sachs (Asia) LLC from February 1997 to July 2000 with his last position as executive director of the Investment Management Division. Mr. Lee was appointed as a committee member of the New Business Committee of the Financial Services Development Council of Hong Kong by the Hong Kong SAR government from March 2013 to March 2019. Mr. Lee was the chairman of the Hong Kong Branch of the Alternative Investment Management Association from September 2004 to August 2012. Mr. Lee was appointed as a member of the Securities and Futures Commission Advisory Committee by the Hong Kong SAR government from June 2007 to May 2009. Mr. Lee received a Bachelor of Applied Science Degree from the University of Pennsylvania in 1991.
- 王国玮
-
王国玮先生，美国国籍。1961年出生，拥有加州理工学院（Caltech）发育生物学博士学位。Wang博士在医疗保健行业有20多年的经验。1998年2月至2000年4月，任BristolMyersSquibb制药研究所药物遗传学主任；2000年5月至2004年9月，任FirstGeneticTrust创始人、执行副总裁；2004年12月至2006年4月，任西门子集团商务发展部部长；2006年4月至2011年7月，任WIHarperGroup董事总经理；2011年8月至今，任OrbiMedAdvisorsLLC合伙人。2019年12月至今，任奥普生物董事。他自2016年4月起担任港交所上市公司AK Medical Holdings Limited董事，自2010年3月起担任深交所上市公司Edan Instruments，Inc.董事（股份代号：300206）。在此之前，Wang博士于2006年4月至2011年7月担任WI Harper Group的医疗保健投资董事总经理。Wang博士拥有北京大学医学院基础医学学士学位和医学博士学位，加州理工学院发育生物学博士学位。于2019年7月1日获委任为来凯医药有限公司非执行董事。
David Guowei Wang,has served as Gracell Biotechnologies Inc. director since March 2020. Dr. Wang has over 20 years of experience in the healthcare industry. Dr. Wang has served as Partner and Senior Managing Director, Asia, of OrbiMed Advisors LLC, since August 2011. He has served as director of AK Medical Holdings Limited, a company listed on the Hong Kong Stock Exchange (Stock Code: 1789) since April 2016, and as director of Edan Instruments, Inc., a company listed in the Shenzhen Stock Exchange (Stock Code: 300206) since March 2010. Prior to that, Dr. Wang served as Managing Director of Healthcare Investment of WI Harper Group from April 2006 to July 2011. Dr. Wang holds a Bachelor's degree in basic medicine and an M.D. from Peking University School of Medicine, and a Ph.D. in Developmental Biology from California Institute of Technology. - 王国玮先生，美国国籍。1961年出生，拥有加州理工学院（Caltech）发育生物学博士学位。Wang博士在医疗保健行业有20多年的经验。1998年2月至2000年4月，任BristolMyersSquibb制药研究所药物遗传学主任；2000年5月至2004年9月，任FirstGeneticTrust创始人、执行副总裁；2004年12月至2006年4月，任西门子集团商务发展部部长；2006年4月至2011年7月，任WIHarperGroup董事总经理；2011年8月至今，任OrbiMedAdvisorsLLC合伙人。2019年12月至今，任奥普生物董事。他自2016年4月起担任港交所上市公司AK Medical Holdings Limited董事，自2010年3月起担任深交所上市公司Edan Instruments，Inc.董事（股份代号：300206）。在此之前，Wang博士于2006年4月至2011年7月担任WI Harper Group的医疗保健投资董事总经理。Wang博士拥有北京大学医学院基础医学学士学位和医学博士学位，加州理工学院发育生物学博士学位。于2019年7月1日获委任为来凯医药有限公司非执行董事。
- David Guowei Wang,has served as Gracell Biotechnologies Inc. director since March 2020. Dr. Wang has over 20 years of experience in the healthcare industry. Dr. Wang has served as Partner and Senior Managing Director, Asia, of OrbiMed Advisors LLC, since August 2011. He has served as director of AK Medical Holdings Limited, a company listed on the Hong Kong Stock Exchange (Stock Code: 1789) since April 2016, and as director of Edan Instruments, Inc., a company listed in the Shenzhen Stock Exchange (Stock Code: 300206) since March 2010. Prior to that, Dr. Wang served as Managing Director of Healthcare Investment of WI Harper Group from April 2006 to July 2011. Dr. Wang holds a Bachelor's degree in basic medicine and an M.D. from Peking University School of Medicine, and a Ph.D. in Developmental Biology from California Institute of Technology.
高管简历
中英对照 | 中文 | 英文- 曹卫
曹卫 自 2017 年 5 月起担任 Gracell Biotechnologies Inc. 董事长兼首席执行官。曹博士在生物技术行业拥有超过 30 年的研发经验。在创立 Gracell Biotechnologies Inc. 公司之前，曹博士与人共同创立了 Cellular Biomedicine Group, Inc.，Cellular Biomedicine Group, Inc.致力于开发用于治疗癌症和退行性疾病的专有细胞疗法，并在 CBMG 担任多个职位，如首席运营官2010 年 8 月至 2016 年 1 月担任董事、首席执行官、董事。曹博士在哈佛医学院病理学系和斯坦福大学医学中心移植中心的免疫药理学领域拥有丰富的研究经验。曹博士拥有中国上海复旦大学医学院医学学士学位和博士学位。弗吉尼亚州里士满弗吉尼亚医学院药理学博士。曹博士拥有 80 多项先进细胞疗法的已授权专利和申请。
Wei Cao,has served as Gracell Biotechnologies Inc. Chairman of the Board and Chief Executive Officer since May 2017. Dr. Cao has over 30 years of research and development experience in the biotechnology industry. Prior to founding Gracell Biotechnologies Inc. company, Dr. Cao co-founded Cellular Biomedicine Group, Inc., a company engaging in developing proprietary cell therapies for the treatment of cancer and degenerative diseases, and served several positions at CBMG, such as chief operating officer, chief executive officer and director, from August 2010 to January 2016. Dr. Cao has extensive research experience in the immune-pharmacology field at Harvard Medical School Department of Pathology and Stanford University Medical Center Transplantation Center. Dr. Cao holds a Bachelor's degree in Medicine from Fudan University Medical College, Shanghai China, and a Ph.D. in Pharmacology from Medical College of Virginia, Richmond Virginia. Dr. Cao holds over 80 issued patents and applications for advanced cell therapies.- 曹卫 自 2017 年 5 月起担任 Gracell Biotechnologies Inc. 董事长兼首席执行官。曹博士在生物技术行业拥有超过 30 年的研发经验。在创立 Gracell Biotechnologies Inc. 公司之前，曹博士与人共同创立了 Cellular Biomedicine Group, Inc.，Cellular Biomedicine Group, Inc.致力于开发用于治疗癌症和退行性疾病的专有细胞疗法，并在 CBMG 担任多个职位，如首席运营官2010 年 8 月至 2016 年 1 月担任董事、首席执行官、董事。曹博士在哈佛医学院病理学系和斯坦福大学医学中心移植中心的免疫药理学领域拥有丰富的研究经验。曹博士拥有中国上海复旦大学医学院医学学士学位和博士学位。弗吉尼亚州里士满弗吉尼亚医学院药理学博士。曹博士拥有 80 多项先进细胞疗法的已授权专利和申请。
- Wei Cao,has served as Gracell Biotechnologies Inc. Chairman of the Board and Chief Executive Officer since May 2017. Dr. Cao has over 30 years of research and development experience in the biotechnology industry. Prior to founding Gracell Biotechnologies Inc. company, Dr. Cao co-founded Cellular Biomedicine Group, Inc., a company engaging in developing proprietary cell therapies for the treatment of cancer and degenerative diseases, and served several positions at CBMG, such as chief operating officer, chief executive officer and director, from August 2010 to January 2016. Dr. Cao has extensive research experience in the immune-pharmacology field at Harvard Medical School Department of Pathology and Stanford University Medical Center Transplantation Center. Dr. Cao holds a Bachelor's degree in Medicine from Fudan University Medical College, Shanghai China, and a Ph.D. in Pharmacology from Medical College of Virginia, Richmond Virginia. Dr. Cao holds over 80 issued patents and applications for advanced cell therapies.
- 谢懿立
谢懿立，自 2020 年 7 月起担任 Gracell Biotechnologies Inc. 首席财务官。谢博士在医疗保健行业和医疗保健投资方面拥有超过 20 年的经验。在加入 Gracell Biotechnologies Inc. 公司之前，谢博士于 2015 年 3 月至 2020 年 7 月在复星集团担任多个领导职务，包括担任复星医疗控股总裁和复星纽约首席代表。谢博士自 2021 年 10 月起担任 Humanigen Inc. Nasdaq： HGEN 的董事。2012 年 2 月至 2015 年 3 月，谢博士担任投资公司 Kinglington Capital 的管理合伙人。 2010 年 4 月至 2012 年 2 月，他共同创立并担任 Locust Walk Capital 的投资组合经理。2009 年 1 月至 2010 年 1 月，谢博士担任全球对冲基金 Scopia Capital 的医疗保健部门负责人。从 2005 年到 2008 年，他担任医疗保健对冲基金 Great Point Partners 的负责人，随后担任董事总经理。谢博士于 2002 年 6 月至 2005 年 7 月担任资产管理公司 Delaware Investments 的股票分析师。谢博士持有中国天津大学学士学位、博士学位。拥有纽约城市大学化学博士学位和宾夕法尼亚大学沃顿商学院工商管理硕士学位。
Yili Kevin Xie,has served as Gracell Biotechnologies Inc. Chief Financial Officer since July 2020. Dr. Xie has over 20 years of experience in healthcare industry and healthcare investment. Prior to joining Gracell Biotechnologies Inc. company, Dr. Xie served in various leadership positions in Fosun Group from March 2015 to July 2020, including as the President of Fosun Healthcare Holdings and Chief Representative of Fosun, New York. Dr. Xie has served as director of Humanigen Inc. (Nasdaq: HGEN) since October 2021. From February 2012 to March 2015, Dr. Xie served as Managing Partner for Kinglington Capital, an investment company. He co-founded and served as Portfolio Manager for Locust Walk Capital from April 2010 to February 2012. From January 2009 to January 2010, Dr. Xie served as Healthcare Sector Head for Scopia Capital, a global hedge fund. From 2005 to 2008, he served as Principal and subsequently Managing Director for Great Point Partners, a healthcare hedge fund. Dr. Xie served as an Equity Analyst for Delaware Investments, an asset management firm, from June 2002 to July 2005. Dr. Xie holds a Bachelor's degree from Tianjin University in China, a Ph.D. in Chemistry from The City University in New York, and an M.B.A. from The Wharton School, University of Pennsylvania.- 谢懿立，自 2020 年 7 月起担任 Gracell Biotechnologies Inc. 首席财务官。谢博士在医疗保健行业和医疗保健投资方面拥有超过 20 年的经验。在加入 Gracell Biotechnologies Inc. 公司之前，谢博士于 2015 年 3 月至 2020 年 7 月在复星集团担任多个领导职务，包括担任复星医疗控股总裁和复星纽约首席代表。谢博士自 2021 年 10 月起担任 Humanigen Inc. Nasdaq： HGEN 的董事。2012 年 2 月至 2015 年 3 月，谢博士担任投资公司 Kinglington Capital 的管理合伙人。 2010 年 4 月至 2012 年 2 月，他共同创立并担任 Locust Walk Capital 的投资组合经理。2009 年 1 月至 2010 年 1 月，谢博士担任全球对冲基金 Scopia Capital 的医疗保健部门负责人。从 2005 年到 2008 年，他担任医疗保健对冲基金 Great Point Partners 的负责人，随后担任董事总经理。谢博士于 2002 年 6 月至 2005 年 7 月担任资产管理公司 Delaware Investments 的股票分析师。谢博士持有中国天津大学学士学位、博士学位。拥有纽约城市大学化学博士学位和宾夕法尼亚大学沃顿商学院工商管理硕士学位。
- Yili Kevin Xie,has served as Gracell Biotechnologies Inc. Chief Financial Officer since July 2020. Dr. Xie has over 20 years of experience in healthcare industry and healthcare investment. Prior to joining Gracell Biotechnologies Inc. company, Dr. Xie served in various leadership positions in Fosun Group from March 2015 to July 2020, including as the President of Fosun Healthcare Holdings and Chief Representative of Fosun, New York. Dr. Xie has served as director of Humanigen Inc. (Nasdaq: HGEN) since October 2021. From February 2012 to March 2015, Dr. Xie served as Managing Partner for Kinglington Capital, an investment company. He co-founded and served as Portfolio Manager for Locust Walk Capital from April 2010 to February 2012. From January 2009 to January 2010, Dr. Xie served as Healthcare Sector Head for Scopia Capital, a global hedge fund. From 2005 to 2008, he served as Principal and subsequently Managing Director for Great Point Partners, a healthcare hedge fund. Dr. Xie served as an Equity Analyst for Delaware Investments, an asset management firm, from June 2002 to July 2005. Dr. Xie holds a Bachelor's degree from Tianjin University in China, a Ph.D. in Chemistry from The City University in New York, and an M.B.A. from The Wharton School, University of Pennsylvania.
- 李文玲
李文玲曾担任 EXUMA Biotech 的首席营销官，在那里她为推进其在美国和亚洲的细胞治疗管道提供战略性医疗和临床领导。 她还曾在辉瑞、赛诺菲、基因泰克和四环医药担任临床开发和医疗事务领导职务。李博士拥有中山医科大学医学博士学位。
Wendy Li,has served as Gracell Biotechnologies Inc. Chief Medical Officer since August 2022. Dr. Li has over 20 years of experience leading all critical aspects of clinical and medical operations at early-stage and large pharmaceutical organizations in the U.S. and China. Her expertise spans both clinical development and medical affairs, including leading early- and late-stage clinical trials for several therapeutic candidates for the treatment of hematological malignancies and solid tumors, and overseeing over 30 successful Investigational New Drug applications (INDs), New Drug Applications (NDAs) and Biologics License Applications (BLAs) that led to several multi-billion-dollar blockbuster drugs. Prior to joining Gracell Biotechnologies Inc. , Dr. Li served as CMO of EXUMA Biotech, where she provided strategic medical and clinical leadership for the advancement of its cell therapy pipeline in the U.S. and Asia. She has also held clinical development and medical affairs leadership positions at Pfizer, Sanofi, Genentech, and Sihuan Pharmaceutical. Dr. Li holds an M.D. from Sun Yat-Sen University of Medical Sciences.- 李文玲曾担任 EXUMA Biotech 的首席营销官，在那里她为推进其在美国和亚洲的细胞治疗管道提供战略性医疗和临床领导。 她还曾在辉瑞、赛诺菲、基因泰克和四环医药担任临床开发和医疗事务领导职务。李博士拥有中山医科大学医学博士学位。
- Wendy Li,has served as Gracell Biotechnologies Inc. Chief Medical Officer since August 2022. Dr. Li has over 20 years of experience leading all critical aspects of clinical and medical operations at early-stage and large pharmaceutical organizations in the U.S. and China. Her expertise spans both clinical development and medical affairs, including leading early- and late-stage clinical trials for several therapeutic candidates for the treatment of hematological malignancies and solid tumors, and overseeing over 30 successful Investigational New Drug applications (INDs), New Drug Applications (NDAs) and Biologics License Applications (BLAs) that led to several multi-billion-dollar blockbuster drugs. Prior to joining Gracell Biotechnologies Inc. , Dr. Li served as CMO of EXUMA Biotech, where she provided strategic medical and clinical leadership for the advancement of its cell therapy pipeline in the U.S. and Asia. She has also held clinical development and medical affairs leadership positions at Pfizer, Sanofi, Genentech, and Sihuan Pharmaceutical. Dr. Li holds an M.D. from Sun Yat-Sen University of Medical Sciences.
- 张苏华
张苏华，曾担任Gracell Biotechnologies Inc.的董事。自2022年7月起担任首席业务官。他拥有超过20年的行业经验，涵盖整个药物开发领域，以及整合关键科学，商业和临床/监管视角的专业知识，以促进包括业务开发交易在内的战略业务决策。他在大型制药公司和小型生物技术公司有着悠久的历史和广泛的交易。加入Gracell之前，从2019年到2022年，他担任位于Rockville Maryland 的NeoImmuneTech（另一家上市的生物技术公司）的首席商务官。在此期间，他通过跨职能领导定义了公司的整体业务战略，并监督业务发展，包括交易发起、交易执行和联盟管理。在加入NeoImmuneTech之前，他于2017年至2019年担任Merus（Nasdaq：MRUS）的战略副总裁。他还曾在诺华（Novartis）、辉瑞（Pfizer）、百时美施贵宝（Bristol-Myers Squibb）和礼来（Eli Lilly）担任各种管理职位，负责产品和投资组合战略、业务发展、全球和美国产品发布以及全球医疗战略。获得哥伦比亚大学博士学位和北京大学学士学位。
Samuel Zhang,has served as Gracell Biotechnologies Inc. Chief Business Officer since July 2022. Dr. Samuel Zhang has over 20 years of industry experience, covering the entire drug development spectrum, and the expertise to integrate key scientific, commercial, and clinical/regulatory perspectives to facilitate strategic business decisions including business development transactions. Dr. Zhang has a long history and broad exposure of deal making at large pharm and small biotech. Prior to joining Gracell, Dr. Zhang served as Chief Business Officer at Rockville Maryland-based NeoImmuneTech, another publicly traded biotech company, from 2019 to 2022. While there, he defined the company's overall business strategy with his cross-functional leadership and oversaw business development including deal initiation, deal execution, and alliance management. Prior to NeoImmuneTech, he was Vice President of Strategy at Merus (Nasdaq: MRUS) from 2017 to 2019. He has also held various management positions at Novartis, Pfizer, Bristol-Myers Squibb (BMS), and Eli Lilly, responsible for product and portfolio strategies, business development, global and U.S. product launches, and global medical strategy.Dr. Zhang received his PhD from Columbia University and his B.S. from Peking University.- 张苏华，曾担任Gracell Biotechnologies Inc.的董事。自2022年7月起担任首席业务官。他拥有超过20年的行业经验，涵盖整个药物开发领域，以及整合关键科学，商业和临床/监管视角的专业知识，以促进包括业务开发交易在内的战略业务决策。他在大型制药公司和小型生物技术公司有着悠久的历史和广泛的交易。加入Gracell之前，从2019年到2022年，他担任位于Rockville Maryland 的NeoImmuneTech（另一家上市的生物技术公司）的首席商务官。在此期间，他通过跨职能领导定义了公司的整体业务战略，并监督业务发展，包括交易发起、交易执行和联盟管理。在加入NeoImmuneTech之前，他于2017年至2019年担任Merus（Nasdaq：MRUS）的战略副总裁。他还曾在诺华（Novartis）、辉瑞（Pfizer）、百时美施贵宝（Bristol-Myers Squibb）和礼来（Eli Lilly）担任各种管理职位，负责产品和投资组合战略、业务发展、全球和美国产品发布以及全球医疗战略。获得哥伦比亚大学博士学位和北京大学学士学位。
- Samuel Zhang,has served as Gracell Biotechnologies Inc. Chief Business Officer since July 2022. Dr. Samuel Zhang has over 20 years of industry experience, covering the entire drug development spectrum, and the expertise to integrate key scientific, commercial, and clinical/regulatory perspectives to facilitate strategic business decisions including business development transactions. Dr. Zhang has a long history and broad exposure of deal making at large pharm and small biotech. Prior to joining Gracell, Dr. Zhang served as Chief Business Officer at Rockville Maryland-based NeoImmuneTech, another publicly traded biotech company, from 2019 to 2022. While there, he defined the company's overall business strategy with his cross-functional leadership and oversaw business development including deal initiation, deal execution, and alliance management. Prior to NeoImmuneTech, he was Vice President of Strategy at Merus (Nasdaq: MRUS) from 2017 to 2019. He has also held various management positions at Novartis, Pfizer, Bristol-Myers Squibb (BMS), and Eli Lilly, responsible for product and portfolio strategies, business development, global and U.S. product launches, and global medical strategy.Dr. Zhang received his PhD from Columbia University and his B.S. from Peking University.